Hyperglycaemia, microangiopathy, diabetes and dementia risk;Hyperglycémie microangiopathie cérébrale, diabète et démence.

Diabetes and Metabolism

Volumn 36, Issue SUPPL. 3, 2010, Pages

  Bourdel Marchasson, I ^a,b   Mouries, A ^a   Helmer, C ^b,c  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM   (France)

Author keywords

Cerebral microangiopathy; Dementia; Hyperglycaemia; Hypertension; Magnetic resonance imaging; Review

Indexed keywords

AGING; ARTICLE; CLINICAL EXAMINATION; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE SEVERITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MICROANGIOPATHY; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK ASSESSMENT; WHITE MATTER;

EID: 78650799322     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(10)70477-8     Document Type: Article

References (70)

1. Bourdel-Marchasson I., Lapre E., Laksir H., Puget E. Insulin resistance, diabetes and cognitive function: consequences for preventative strategies. Diabetes Metab 2010, 36:173-181.
2. Biessels G.J., Staekenborg S., Brunner E., Brayne C., Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006, 5:64-74.
3. Gorelick P.B., Bowler J.V. Advances in vascular cognitive impairment. Stroke 2008, 41:e93-e98.
4. Staekenborg S.S., van Straaten E.C., van der Flier W.M., Lane R., Barkhof F., Scheltens P. Small vessel versus large vessel vascular dementia: risk factors and MRI findings. J Neurol 2008, 255:1644-1651. discussion 1813-1814.
5. Censori B., Manara O., Agostinis C., Camerlingo M., Casto L., Galavotti B., et al. Dementia after first stroke. Stroke 1996, 27:1205-1210.
6. Desmond D.W., Moroney J.T., Paik M.C., Sano M., Mohr J.P., Aboumatar S., et al. Frequency and clinical determinants of dementia after ischemic stroke. Neurology 2000, 54:1124-1131.
7. Tatemichi T.K., Desmond D.W., Paik M., Figueroa M., Gropen T.I., Stern Y., et al. Clinical determinants of dementia related to stroke. Ann Neurol 1993, 33:568-575.
8. Desmond D.W., Moroney J.T., Sano M., Stern Y. Recovery of cognitive function after stroke. Stroke 1996, 27:1798-1803.
9. van den Berg E., de Craen A.J., Biessels G.J., Gussekloo J., Westendorp R.G. The impact of diabetes mellitus on cognitive decline in the oldest of the old: a prospective population-based study. Diabetologia 2006, 49:2015-2023.
10. Xu W.L., von Strauss E., Qiu C.X., Winblad B., Fratiglioni L. Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. Diabetologia 2009, 52:1031-1039.
11. Gao L., Matthews F.E., Sargeant L.A., Brayne C. An investigation of the population impact of variation in HbA1c levels in older people in England and Wales: from a population based multi-centre longitudinal study. BMC Public Health 2008, 8:54.
12. Staekenborg S.S., de Waal H., Admiraal-Behloul F., Barkhof F., Reiber J.H., Scheltens P., et al. Neurological signs in relation to white matter hyperintensity volumes in memory clinic patients. Dement Geriatr Cogn Disord 2010, 29:301-308.
13. Syrjala P., Luukinen H., Pyhtinen J., Tolonen U. Neurological diseases and accidental falls of the aged. J Neurol 2003, 250:1063-1069.
14. Piguet O., Ridley L., Grayson D.A., Bennett H.P., Creasey H., Lye T.C., et al. Are MRI white matter lesions clinically significant in the "old-old" ? Evidence from the Sydney Older Persons Study. Dement Geriatr Cogn Disord 2003, 15:143-150.
15. Waite L.M., Grayson D.A., Piguet O., Creasey H., Bennett H.P., Broe G.A. Gait slowing as a predictor of incident dementia: 6-year longitudinal data from the Sydney Older Persons Study. J Neurol Sci 2005, 229-230. 89-93.
16. Wakefield D.B., Moscufo N., Guttmann C.R., Kuchel G.A., Kaplan R.F., Pearlson G., et al. White matter hyperintensities predict functional decline in voiding, mobility, and cognition in older adults. J Am Geriatr Soc 2010, 58:275-281.
17. Gunning-Dixon F.M., Brickman A.M., Cheng J.C., Alexopoulos G.S. Aging of cerebral white matter: a review of MRI findings. Int J Geriatr Psychiatry 2009, 24:109-117.
18. Firbank M.J., Wiseman R.M., Burton E.J., Saxby B.K., O'Brien J.T., Ford G.A. Brain atrophy and white matter hyperintensity change in older adults and relationship to blood pressure. Brain atrophy, WMH change and blood pressure. J Neurol 2007, 254:713-721.
19. Breteler M.M., van Swieten J.C., Bots M.L., Grobbee D.E., Claus J.J., van den Hout J.H., et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology 1994, 44:1246-1252.
20. Brickman A.M., Zimmerman M.E., Paul R.H., Grieve S.M., Tate D.F., Cohen R.A., et al. Regional white matter and neuropsychological functioning across the adult lifespan. Biol Psychiatry 2006, 60:444-453.
21. Schmidt R., Ropele S., Ferro J., Madureira S., Verdelho A., Petrovic K., et al. Diffusion-weighted imaging and cognition in the leukoariosis and disability in the elderly study. Stroke 2010, 41:e402-e408.
22. Silbert L.C., Howieson D.B., Dodge H., Kaye J.A. Cognitive impairment risk: white matter hyperintensity progression matters. Neurology 2009, 73:120-125.
23. Prins N.D., van Dijk E.J., den Heijer T., Vermeer S.E., Koudstaal P.J., Oudkerk M., et al. Cerebral white matter lesions and the risk of dementia. Arch Neurol 2004, 61:1531-1534.
24. Schneider J.A., Boyle P.A., Arvanitakis Z., Bienias J.L., Bennett D.A. Subcortical infarcts, Alzheimer's disease pathology, and memory function in older persons. Ann Neurol 2007, 62:59-66.
25. Lopez O.L., Jagust W.J., Dulberg C., Becker J.T., DeKosky S.T., Fitzpatrick A., et al. Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Arch Neurol 2003, 60:1394-1399.
26. Werring D.J., Gregoire S.M., Cipolotti L. Cerebral microbleeds and vascular cognitive impairment. J Neurol Sci 2010, Sep 16 [Epub ahead of print].
27. Pettersen J.A., Sathiyamoorthy G., Gao F.Q., Szilagyi G., Nadkarni N.K., St George-Hyslop P., et al. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch Neurol 2008, 65:790-795.
28. Tiehuis A.M., van der Graaf Y., Visseren F.L., Vincken K.L., Biessels G.J., Appelman A.P., et al. Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease. Stroke 2008, 39:1600-1603.
29. van der Flier W.M., van Straaten E.C., Barkhof F., Ferro J.M., Pantoni L., Basile A.M., et al. Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study. J Neurol Neurosurg Psychiatry 2005, 76:1497-1500.
30. Verdelho A., Madureira S., Ferro J.M., Basile A.M., Chabriat H., Erkinjuntti T., et al. Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. J Neurol Neurosurg Psychiatry 2007, 78:1325-1330.
31. Verdelho A., Madureira S., Moleiro C., Ferro J.M., Santos C.O., Erkinjuntti T., et al. White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. Neurology 2010, 75:160-167.
32. Korf E.S., White L.R., Scheltens P., Launer L.J. Brain aging in very old men with type 2 diabetes: the Honolulu-Asia Aging Study. Diabetes Care 2006, 29:2268-2274.
33. Fushimi H., Inoue T., Yamada Y., Udaka F., Kameyama M. Asymptomatic cerebral small infarcts (lacunae), their risk factors and intellectual disturbances. Diabetes 1996, 45(Suppl 3):S98-S100.
34. Lemmens R., Gorner A., Schrooten M., Thijs V. Association of apolipoprotein E epsilon2 with white matter disease but not with microbleeds. Stroke 2007, 38:1185-1188.
35. Gold S.M., Dziobek I., Sweat V., Tirsi A., Rogers K., Bruehl H., et al. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia 2007, 50:711-719.
36. den Heijer T., Vermeer S.E., van Dijk E.J., Prins N.D., Koudstaal P.J., Hofman A., et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003, 46:1604-1610.
37. Schmidt R., Launer L.J., Nilsson L.G., Pajak A., Sans S., Berger K., et al. Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study. Diabetes 2004, 53:687-692.
38. Nelson P.T., Smith C.D., Abner E.A., Schmitt F.A., Scheff S.W., Davis G.J., et al. Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim Biophys Acta 2009, 1792:454-469.
39. Ahtiluoto S., Polvikoski T., Peltonen M., Solomon A., Tuomilehto J., Winblad B., et al. Diabetes, Alzheimer disease, and vascular dementia: A population-based neuropathologic study. Neurology 2010, 75:1195-1202.
40. Rasgon N.L., Kenna H.A., Wroolie T.E., Kelley R., Silverman D., Brooks J., et al. Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease. Neurobiol Aging 2009, Dec 24 [Epub ahead of print].
41. Matsuzaki T., Sasaki K., Tanizaki Y., Hata J., Fujimi K., Matsui Y., et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 2010, 75:764-770.
42. Skoog I., Wallin A., Fredman P., Hesse C., Aevarsson O., Karlsson I., et al. A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology 1998, 50:966-971.
43. Dankbaar J.W., Hom J., Schneider T., Cheng S.C., Lau B.C., van der Schaaf I., et al. Age - and anatomy-related values of blood-brain barrier permeability measured by perfusion-CT in non-stroke patients. J Neuroradiol 2009, 36:219-227.
44. Hawkins B.T., Lundeen T.F., Norwood K.M., Brooks H.L., Egleton R.D. Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia 2007, 50:202-211.
45. Huber J.D., VanGilder R.L., Houser K.A. Streptozotocin-induced diabetes progressively increases blood-brain barrier permeability in specific brain regions in rats. Am J Physiol Heart Circ Physiol 2006, 291:H2660-H2668.
46. Kearney-Schwartz A., Rossignol P., Bracard S., Felblinger J., Fay R., Boivin J.M., et al. Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints. Stroke 2009, 40:1229-1236.
47. Kwa V.I., van der Sande J.J., Stam J., Tijmes N., Vrooland J.L. Retinal arterial changes correlate with cerebral small-vessel disease. Neurology 2002, 59:1536-1540.
48. Kwon H.M., Kim B.J., Oh J.Y., Kim S.J., Lee S.H., Oh B.H., et al. Retinopathy as an indicator of silent brain infarction in asymptomatic hypertensive subjects. J Neurol Sci 2007, 252:159-162.
49. Brands A.M., Biessels G.J., de Haan E.H., Kappelle L.J., Kessels R.P. The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care 2005, 28:726-735.
50. Wessels A.M., Simsek S., Remijnse P.L., Veltman D.J., Biessels G.J., Barkhof F., et al. Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. Diabetologia 2006, 49:2474-2480.
51. Weinger K., Jacobson A.M., Musen G., Lyoo I.K., Ryan C.M., Jimerson D.C., et al. The effects of type 1 diabetes on cerebral white matter. Diabetologia 2008, 51:417-425.
52. Manschot S.M., Biessels G.J., de Valk H., Algra A., Rutten G.E., van der Grond J., et al. Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes. Diabetologia 2007, 50:2388-2397.
53. Yaffe K., Blackwell T., Whitmer R.A., Krueger K., Barrett Connor E. Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Aging 2006, 10:293-295.
54. Gallacher J.E., Pickering J., Elwood P.C., Bayer A.J., Yarnell J.W., Ben- Shlomo Y. Glucoregulation has greater impact on cognitive performance than macro-vascular disease in men with type 2 diabetes: data from the Caerphilly study. Eur J Epidemiol 2005, 20:761-768.
55. Ryan C.M., Freed M.I., Rood J.A., Cobitz A.R., Waterhouse B.R., Strachan M.W. Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care 2006, 29:345-351.
56. Abbatecola A.M., Rizzo M.R., Barbieri M., Grella R., Arciello A., Laieta M.T., et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006, 67:235-240.
57. Rizzo M.R., Marfella R., Barbieri M., Boccardi V., Vestini F., Lettieri B., et al. Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients. Diabetes Care 2010, 33:2169-2174.
58. Papanikolaou Y., Palmer H., Binns M.A., Jenkins D.J., Greenwood C.E. Better cognitive performance following a low-glycaemic-index compared with a high-glycaemic-index carbohydrate meal in adults with type 2 diabetes. Diabetologia 2006, 49:855-862.
59. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
60. Lee M.Y., Wang Y., Vanhoutte P.M. Senescence of cultured porcine coronary arterial endothelial cells is associated with accelerated oxidative stress and activation of NFkB. J Vasc Res 2010, 47:287-298.
61. El-Osta A., Brasacchio D., Yao D., Pocai A., Jones P.L., Roeder R.G., et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008, 205:2409-2417.
62. Sanz C., Andrieu S., Sinclair A., Hanaire H., Vellas B. Diabetes is associated with a slower rate of cognitive decline in Alzheimer disease. Neurology 2009, 73:1359-1366.
63. Richard E., Van den Heuvel E., Moll van Charante E.P., Achthoven L., Vermeulen M., Bindels P.J., et al. Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress. Alzheimer Dis Assoc Disord 2009, 23:198-204.
64. Bruandet A., Richard F., Bombois S., Maurage C.A., Deramecourt V., Lebert F., et al. Alzheimer disease with cerebrovascular disease and vascular dementia: clinical features and course compared with Alzheimer disease. J Neurol Neurosurg Psychiatry 2009, 80:133-139.
65. Plastino M., Fava A., Pirritano D., Cotronei P., Sacco N., Sperli T., et al. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. J Neurol Sci 2010, 288:112-116.
66. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
67. Patel A., MacMahon S., Chalmers J., Neal B., Woodward M., Billot L., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829-840.
68. Casey R.G., Joyce M., Roche-Nagle G., Chen G., Bouchier-Hayes D. Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease. J Surg Res 2005, 123:176-181.
69. van den Heuvel D.M., ten Dam V.H., de Craen A.J., Admiraal-Behloul F., Olofsen H., Bollen E.L., et al. Increase in periventricular white matter hyperintensities parallels decline in mental processing speed in a non-demented elderly population. J Neurol Neurosurg Psychiatry 2006, 77:149-153.
70. ten Dam V.H., Box F.M., de Craen A.J., van den Heuvel D.M., Bollen E.L., Murray H.M., et al. Lack of effect of pravastatin on cerebral blood flow or parenchymal volume loss in elderly at risk for vascular disease. Stroke 2005, 36:1633-1636.